Nanotech radiation therapy technology developer Nanobiotix said it will launch a trial for its NBTXR3 nanoparticle for use in treating late-stage head and neck cancers.
NBTXR3 initially received the European CE Mark for treatment of locally advanced soft-tissue sarcoma, and the company said it is now focusing on applying the nanoparticle to the treatment of head and neck cancers.
In addition, the firm said that it's evaluating the use of NBTXR3 in immuno-oncology. Nanobiotix's collaborators -- the University of Texas MD Anderson Cancer Center in Houston and PharmaEngine in Asia -- also are continuing to develop the nanoparticle for other indications, such as lung, esophageal, pancreatic, and other cancers, the company said.
